{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:45:53Z","timestamp":1787499953786,"version":"build-2736575974"},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Baricitinib is a Janus kinase inhibitor that has been approved by the US Food and Drugs Administration for the treatment of severe alopecia areata (AA) in adults. However, the clinical trials that demonstrated the efficacy of baricitinib in the treatment of severe AA did not include men aged &amp;gt; 60\u2005years or women aged &amp;gt; 70\u2005years. We retrospectively assessed the efficacy and safety of baricitinib in 14 patients aged \u2265 65\u2005years with moderate-to-severe AA. After a mean (SD) duration of 18.5 (11.9) months, a 72% reduction in mean Severity of Alopecia Tool score from baseline was observed. Partial or complete eyebrow and eyelash hair was observed in 57% and 43% of patients, respectively. The adverse effects of baricitinib were mild. No cases of venous thromboembolism, major adverse cardiovascular events or malignancy were reported.<\/jats:p>","DOI":"10.1093\/ced\/llae033","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T23:59:08Z","timestamp":1706054348000},"page":"875-878","source":"Crossref","is-referenced-by-count":7,"title":["Treatment of moderate-to-severe alopecia areata in patients over the age of 65\u2005years with baricitinib"],"prefix":"10.1093","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6826-131X","authenticated-orcid":false,"given":"Gia Toan","family":"Tang","sequence":"first","affiliation":[{"name":"The University of Melbourne , Parkville, VIC , Australia"},{"name":"Sinclair Dermatology , East Melbourne, VIC , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daranporn","family":"Triwongwaranat","sequence":"additional","affiliation":[{"name":"Sinclair Dermatology , East Melbourne, VIC , Australia"},{"name":"Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University , Bangkok , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Sinclair","sequence":"additional","affiliation":[{"name":"The University of Melbourne , Parkville, VIC , Australia"},{"name":"Sinclair Dermatology , East Melbourne, VIC , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shobha","family":"Joseph","sequence":"additional","affiliation":[{"name":"Sinclair Dermatology , East Melbourne, VIC , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Eisman","sequence":"additional","affiliation":[{"name":"Sinclair Dermatology , East Melbourne, VIC , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepani","family":"Rathnayake","sequence":"additional","affiliation":[{"name":"Sinclair Dermatology , East Melbourne, VIC , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanathy","family":"Varathan","sequence":"additional","affiliation":[{"name":"Sinclair Dermatology , East Melbourne, VIC , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Trindade de Carvalho","sequence":"additional","affiliation":[{"name":"Sinclair Dermatology , East Melbourne, VIC , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bevin","family":"Bhoyrul","sequence":"additional","affiliation":[{"name":"Sinclair Dermatology , East Melbourne, VIC , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"key":"2024071909334018400_llae033-B1","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"key":"2024071909334018400_llae033-B2","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jaad.2022.12.033","article-title":"Treatment of moderate-to-severe alopecia areata in adolescents with baricitinib: a retrospective review of 29 patients","volume":"88","author":"Moussa","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2024071909334018400_llae033-B3","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/bjd\/ljad118","article-title":"Treatment of moderate-to-severe alopecia areata with baricitinib in preadolescent children","volume":"189","author":"Asfour","year":"2023","journal-title":"Br J Dermatol"},{"key":"2024071909334018400_llae033-B4","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"2024071909334018400_llae033-B5","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40257-023-00764-w","article-title":"Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2)","volume":"24","author":"Kwon","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"2024071909334018400_llae033-B6","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/bjd\/ljad253","article-title":"When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials","volume":"189","author":"King","year":"2023","journal-title":"Br J Dermatol"},{"key":"2024071909334018400_llae033-B7","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jaad.2019.08.080","article-title":"Combination tofacitinib and oral minoxidil treatment for severe alopecia areata","volume":"85","author":"Wambier","year":"2021","journal-title":"J Am Acad Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae033\/57245224\/llae033.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/8\/875\/58594086\/llae033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/8\/875\/58594086\/llae033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T05:33:50Z","timestamp":1721367230000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/49\/8\/875\/7589157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":7,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,1,25]]},"published-print":{"date-parts":[[2024,7,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae033","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,1,25]]}}}